The application of imatinib mesylate (IMT), an ATP-competitive selective BCR-ABL tyrosine kinase inhibitor, significantly improved survival in most CML patients [2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.